Release date: 2016-12-14
The American Society of Hematology (ASH) recently presented this year's Ernest Botler Award. The winners are Professor Chen Wei from the Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University, and Professor Hugues de Thé from St. Louis Hospital in Paris. Recognize their outstanding achievements in the basic and clinical research of acute promyelocytic leukemia (APL).
It is reported that APL was a very vicious blood disease with extremely high mortality and high mortality. Chen Yu's team used all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) to jointly target APL, which made the 5-year disease-free survival rate of this disease jump to more than 90%, reaching the basic "cure" standard. At the same time, it is revealed from the molecular mechanism how ATRA and arsenic act on APL pathogenic molecule PML/RARα, respectively, to induce differentiation and apoptosis of leukemia cells, so as to achieve the purpose of disease treatment. This is a true combination of clinical medicine and basic biology. It is a model of the combination of Eastern traditional medicine and Western medicine. It has opened an important chapter in the transformation and treatment of malignant blood diseases.
Chen Wei introduced the development stages of clinical application of ATRA and arsenic in the treatment of APL patients led by Chinese scholars, and continued the process of conceptual design innovation and optimization of clinical trial programs, emphasizing the important enlightenment of traditional Chinese medicine in the treatment concept and practice of leukemia. , based on the clinical application of modern molecular cells and overall level system research results, as well as the latest achievements in large multi-center clinical research in China, Europe and the United States. The results show that ATRA and arsenic combined with targeted therapy can achieve more than 95% long-term disease-free survival in low- and moderate-risk APL patients without the need for chemotherapy. At the same time, Chen Hao also proposed that reducing the early mortality rate of APL patients and early identification and intervention of high-risk patients with recurrence will remain a long-term and long-term task. As an example of precision medicine, APL collaborative targeted therapy should be combined with the establishment and improvement of the universal health insurance system, and the research results will be extended to countries around the world including developing countries, thus bringing more people to the gospel.
Source: Technology Daily
Polo Shirt,Red Polo Shirt,Short Sleeved Polo Shirts,Men'S Short Sleeved Polo Shirts
Xinhui Jielide Garment Factory , https://www.ntgfwear.com